Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Introduction: New medication classes are needed to improve treatment effectiveness in the depressed phase of bipolar disorder (BD). Extant evidence suggests that BD is characterised by neural changes such as dendritic remodelling and glial and neuronal cell loss. These changes have been hypothesised to result from chronic inflammation. The principal aims of the proposed research is to evaluate the antidepressant efficacy in bipolar depression of minocycline, a drug with neuroprotective and immune-modulating properties, and of aspirin, at doses expected to selectively inhibit cyclooxygenase 1 (COX-1). Methods and analysis: 120 outpatients between 18 and 55 years of age, who meet DSM-IV-TR criteria for BD (type I or II) and for a current major depressive episode will be recruited to take part in a randomised, double-blind, placebo-controlled, parallel-group, proof-of-concept clinical trial following a 2×2 design. As adjuncts to existing treatment, subjects will be randomised to receive one of the four treatment combinations: placebo-minocycline plus placebo-aspirin, active-minocycline plus placebo-aspirin, placebo-minocycline plus active-aspirin or active-minocycline plus active-aspirin. The dose of minocycline and aspirin is 100 mg twice daily and 81 mg twice daily, respectively. Antidepressant response will be evaluated by assessing changes in the Montgomery–Asberg Depression Rating Scale scores between baseline and the end of the 6-week trial. As secondary outcome measures, the anti-inflammatory effects of minocycline and aspirin will be tested by measuring pre-treatment and post-treatment levels of C reactive protein and inflammatory cytokines. Ethics and dissemination: Minocycline has been widely used as an antibiotic in doses up to 400 mg/day. Low-dose aspirin has been safely used on a worldwide scale for its role as an antithrombotic and thrombolytic. The study progress will be overseen by a Data, Safety and Monitoring Board, which will meet once every 6 months. Results of the study will be published in peer-reviewed publications. Trial registration number: Clinical Trials.gov: NCT01429272.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 5×
“The immunologic and glutamatergic models of BD are complementary because a proinflammatory state is one potential cause of excitotoxicity.(27) Peripheral inflammatory signals activate microglia in the brain, inducing an inflammatory cascade of cytokines and free radicals.”
BackgroundInfluentialAssociations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
Self-citationO'Connor, J. C., Lawson, M. A., André, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K. W., & Dantzer, R. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002148 · Cited by 1,278 · cited 1×
“61 Levine et al 62 presented the case of a 66-year-old woman with severe BD, who observed that the tetracycline she took for an infection alleviated her depression.”
BackgroundClinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Bailey, M. T., Dowd, S. E., Galley, J. D., Hufnagle, A. R., Allen, R. G., & Lyte, M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.023 · Cited by 1,123
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069 · cited 1×
“Moreover, anti-TNF therapy (for psoriasis) can improve mood.(22) Since proinflammatory cytokines can alter brain function, these data are compatible with evidence that an activated inflammatory response system exists in mood disorders which plays a role in their pathophysiology.”
BackgroundTetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 1×
“…apoptosis of neuro ns in vitro, 42 prevents ischaemia-induced activation of microglia in gerbils, 43 increases hippocampal neuron survival, 44 neurological function in mice with traumatic brain injury 45 and in fragile X syndrome, 46 reduces proin-flammatory cytokine expression and…”
BackgroundDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“Finally, ketamine induced a rapid sustained antidepressant effect in BD(15) 16 and riluzole showed promising results in treatment-resistant depression.(15) 16 One potential cause of the disruption in glutamatergic signalling in BD is dysregulation of the immune system.”
BackgroundTikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958 · cited 1×
“41 Minocycline has neuroprotective and anti-inflammatory properties Minocycline prevents glutamate-induced apoptosis of neuro ns in vitro, 42 prevents ischaemia-induced activation of microglia in gerbils, 43 increases hippocampal neuron survival, 44 neurological function in mice with traumatic brain…”
BackgroundTohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630 · cited 2×
“Kyn is in turn metabolised into quinolinic acid (Quin), a potent NMDA receptor agonist, and neuromodulator involved in lipid peroxidation, which can induce neuronal damage via oxidative stress and overstimulation of NMDA receptors.(30) Consistent with inflammation-related shunt towards Kyn metabolism, the plasma trypt…”
BackgroundMaes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.014 · Cited by 544
Bipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide
Savitz, J., & Drevets, W. C. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.01.004 · Cited by 494 · cited 7×
“Given the exaggerated death rate from cardiovascular (CV) events in BD, this action potentially is advantageous in the management of BD.”
BackgroundInfluentialSelf-citationBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 1×
“…in gerbils, 43 increases hippocampal neuron survival, 44 neurological function in mice with traumatic brain injury 45 and in fragile X syndrome, 46 reduces proin-flammatory cytokine expression and improves neurological function and locomotor activity in rats with spinal cord injury, 47…”
BackgroundAbsence of diurnal variation of C-reactive protein concentrations in healthy human subjects
Meier-Ewert, H. K., Ridker, P. M., Rifai, N., Price, N., Dinges, D. F., & Mullington, J. M. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.3.426 · Cited by 410
ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS
Mallinckrodt, C. H., Clark, W. S., & David, S. R. (2001) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-100104194 · Cited by 398
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387 · cited 2×
“This also is the dose used in a recent schizophrenia treatment trial.(58) The associated placebo capsules match the appearance of the 100 mg minocycline capsule.”
BackgroundMethodTranylcypromine versus imipramine in anergic bipolar depression
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.7.910 · Cited by 360
Meta-analysis of the placebo response in antidepressant trials.
Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.029 · Cited by 346 · cited 1×
“50 for an antidepressant treatment.(85) We calculated that in order to detect an effect size of 0.”
BackgroundCytokines and Glucocorticoid Receptor Signaling
Pace, T. W. W., & Miller, A. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04984.x · Cited by 339
IL-6 and its circadian secretion in humans
Vgontzas, A. N., Bixler, E. O., Lin, H.-M., Prolo, P., Trakada, G., & Chrousos, G. P. (2005) · Neuroimmunomodulation · doi:10.1159/000084844 · Cited by 338 · cited 1×
“The serum CRP concentration shows minimal diurnal variability in adults(82) but IL-6 and other cytokine levels vary across time of day.(83) To minimise cytokine measurement variability due to circadian fluctuations, we will schedule patient assessment sessions at the same time each day.”
BackgroundPadmos, R. C., Hillegers, M. H. J., Knijff, E. M., Vonk, R., Bouvy, A., Staal, F. J. T., de Ridder, D., Kupka, R. W., Nolen, W. A., & Drexhage, H. A. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.395 · Cited by 336 · cited 2×
“Microarray gene expression profiles in purified CD14+ monocytes from whole blood of BD subjects, offspring of BD parents and healthy controls (HCs) displayed a distinct mRNA signature representing genes from inflammatory and inflammation-related pathways.(32) The signature showed >80% sensitivity and specificity in BD…”
BackgroundMethodMMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
Siddiqui, O., Hung, H. M. J., & O'Neill, R. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400802609797 · Cited by 301 · cited 1×
“A Mixed-Effect Model Repeated Measure (MMRM)(80) will be used to derive missing data points as this method has been shown to be superior to last observation carried forward which can inflate the type I error rates.(81) The last observation carried forward and observed cases approaches to data imputation will be used p…”
MethodMaier, S. F. (2003) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(03)00032-1 · Cited by 300 · cited 1×
“Peripheral cytokines cross the BBB and can propagate signals across the BBB in the form of small, freely diffusible lipophilic molecules such as prostaglandins, which induce the production of cytokines from glia.(77) The measurement of peripheral markers of inflammation thus serves as a valid, if indirect assessment o…”
Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298
Drexhage, R. C., Knijff, E. M., Padmos, R. C., Heul-Nieuwenhuijzen, L. V. D., Beumer, W., Versnel, M. A., & Drexhage, H. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.144 · Cited by 263
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.2.195 · Cited by 167
Kosten, T. A., Galloway, M. P., Duman, R. S., Russell, D. S., & D'Sa, C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301527 · Cited by 165 · cited 1×
“39 BCL-2 represses apoptosis induced by cytotoxic insults.”
BackgroundMaes, M. (1992) · Journal of Affective Disorders · doi:10.1016/0165-0327(92)90066-f · Cited by 147
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146 · cited 1×
“This group then conducted a 4-week trial with minocycline (150 mg/day) in 22 patients with schizophrenia to evaluate its efficacy as an adjunct to antipsychotic drugs.(57) Patients showed a significant improvement in positive and negative symptoms.”
MethodThe Potential of Minocycline for Neuroprotection in Human Neurologic Disease
Zemke, D., & Majid, A. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000150867.98887.3e · Cited by 125 · cited 3×
“…tetracycline that may prevent both glutamate-induced excitotoxicity and cytokine-induced inflammation in the CNS and periphery Minocycline has high lipophilicity enabling efficient transfer across the blood-brain barrier (BBB) 33 its concentration in CSF reaches 11% e 56% of plasma concentrations.”
BackgroundInfluentialAn update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Zanchetti, A., Hansson, L., Leonetti, G., Rahn, K.-H., Ruilope, L., Warnold, I., & Wedel, H. (2002) · Journal of Hypertension · doi:10.1097/00004872-200205000-00038 · Cited by 89
Pariante, C. M., Pearce, B. D., Pisell, T. L., Sanchez, C. I., Po, C., Su, C., & Miller, A. H. (1999) · Endocrinology · doi:10.1210/en.140.9.4359 · Cited by 40
Cited by
The kynurenine pathway: a finger in every pie
Savitz, J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0414-4 · Cited by 756
Self-citationInflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609
Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness
Berk, M., Dean, O., Drexhage, H., McNeil, J. J., Moylan, S., O'Neil, A., Davey, C. G., Sanna, L., & Maes, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-74 · Cited by 391
Role of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257
“Currently, ongoing RCTs are investigating the effect of minocycline add-on treatment for the management of depressive symptoms in patients with treatment-resistant depression (Husain et al , 2015), MDD (Dean et al , 2014), and bipolar depression (Savitz et al , 2012).”
Rosenblat, J. D., Kakar, R., Berk, M., Kessing, L. V., Vinberg, M., Baune, B. T., Mansur, R. B., Brietzke, E., Goldstein, B. I., & McIntyre, R. S. (2016) · Bipolar Disorders · doi:10.1111/bdi.12373 · Cited by 199
Metadata
- Authors
- Savitz, J., Preskorn, S., Teague, T. K., Drevets, D., Yates, W., & Drevets, W.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2012
- Volume
- 2
- Issue
- 1
- Pages
- e000643
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2164373099
- Cited by
- 73
- References
- 40
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.